As successive grades are diagnosed, the incidence of FGFR3 mutations decreases: non-invasive, grade 1 bladder cancer has the most frequent occurrence of FGFR3 mutations (~ 61%), then non-invasive, grade 2 bladder cancer (~ 58%), followed by non-invasive, grade 3 bladder cancer (~ 34%), lamina propria-invasive grade 3 (~ 17%), and, last, high-grade tumors, which demonstrate FGFR3 mutations in only about 11% of cases [124–126]. The gene discussed is FGFR3; the disease is urinary bladder cancer.